No registrations found.
ID
Source
Brief title
Health condition
Central Retinal Vein Occlusion (CRVO)
Sponsors and support
Intervention
Outcome measures
Primary outcome
BCVA on ETDRS chart.
Secondary outcome
Reduction in:
1. Neovascular changes;
2. Neovascular glaucoma;
3. Rates of development of macular oedema.
Background summary
Central retinal vein occlusion (CRVO) is a frequent retinal disorder. In the literature ischemic CRVO (iCRVO) and non-ischemic CRVO with an initial visual acuity of lower than 0.1 snellen have a poor chance to improve visual acuity. At this moment no curative treatment is available. Current therapy is aimed at the prevention of neovascular glaucoma.
Preliminary results by Weiss et al. suggest a benefit, i.e. improvement of visual acuity, by branch retinal vein cannulation with injection of 4 ml of 200 ìg/ml rt-PA, a potent thrombolytic agent.
In ischemic stroke or acute myocard infarction, a dose of 100 mg rt-PA is routinely administrated by IV perfusion.
In the reports using the intra-retinal vein injection of a total dose of 0.8 mg rt-PA, no extra-ocular adverse effects were noted.
However, the studies published are non-controlled, non randomised case series, in which it is unclear if spontaneous resolution of non-ischemic CRVO (with a visual acuity higher than 0.1, which is known to improve spontaneously) confounds results.
Regarding the frequency of the disease, the poor visual acuity outcome, the lack of curative treatment, and the promising results of non-controlled case series, a rigorous prospective randomized study of the described technique is indicated.
In this phase, only the patients with minimal chance of visual acuity improvement, (i.e. the patients with a initial visual acuity of less than 0.1), are included in the study. If proven satisfactory, future studies could include patients with better initial visual acuity.
Study objective
rt-PA administration by retinal branch vein way in CRVO patients improves final BCVA.
Intervention
Injection of rt-PA (0.2 mg/ml, 4 ml) in retinal branch vein.
Schiedamsevest 180
K.A. Overdam, van
Rotterdam 3011 BH
The Netherlands
+31 (0)10 4017777
kvoverdam@oogziekenhuis.nl
Schiedamsevest 180
K.A. Overdam, van
Rotterdam 3011 BH
The Netherlands
+31 (0)10 4017777
kvoverdam@oogziekenhuis.nl
Inclusion criteria
1. Informed consent;
2. >18 years of age;
3. Adequate birth control (if not post-menopausal or sterilised) during a 2 week pre- and 6 week post-op period if assigned to vitreoretinal surgery;
4. Subjective decrease in visual acuity starting within 4 weeks prior to study start, due to CRVO, clinically evident by fundoscopy;
5. Non-perfused or perfused CRVO with a visual acuity of less than 20/200.
Note : Pseudophakic patients are allowed to participate in this study.
Exclusion criteria
1. Inability to visualize fundus due to corneal or important lenticular opacities;
2. Inability to obtain photographs of CRVO due to allergy to fluorescein or lack of veinous access;
3. As visual acuity prognosis is better and risk for neovascularisation is reduced in perfused CRVO, patients with a visual acuity > 20/200 will not be included;
4. Presence of iris neovascularisation (> grade 1) or anterior chamber angle (>grade 1) at the moment of presentation;
5. Other retinal or ophthalmic disorders that could influence the macular area;
6. Disorders that could be complicated by iris or retinal neovascularisation;
7. Disorders that could be complicated by any form of secondary glaucoma;
8. Prescription of acetazolamide or high dose systemic steroid (> 10 mg prednisone daily) or other anti-inflammatory medication (eg. MTX, Imuran, Endoxan, Humira, Kineret, Infliximab, Thalidomide) except NSAIDs;
9. Participation in another clinical ophthalmic trial;
10. Any surgery of the orbit, ocular adnexae or eye scheduled during the period the study (except for cataract surgery, developed after inclusion to a degree as outlined by the protocol);
11. Monophthalmia or other known ophthalmic disorder in the fellow eye that could be complicated by blindness;
12. Previous retinal surgery;
13. High myopia (-8 D spherical equivalent or more);
14. Macula affecting drugs.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL646 |
| NTR-old | NTR707 |
| Other | : OZR-2005-14 |
| ISRCTN | ISRCTN58543190 |